Fennec Pharmaceuticals (FENC) CFO Robert Andrade Receives 1,703 Shares

What Happened
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), was reported on Aug 31, 2026 to have received 1,703 shares (transaction code A) at an acquisition price of $0.00 — total reported cash value $0. These shares were released from restrictions tied to prior awards rather than bought on the open market.

Key Details

• Transaction date: 2026-08-31; reported on the Form 4 filed 2026-08-31.
• Shares acquired: 1,703; Price per share: $0.00; Reported cash value: $0.
• Footnote: Shares were released from restriction from awards dated 5/16/2024 and 3/28/2025.
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: filed on the same date as the report (no late-filing indication in this record).

Context
This was a release/vesting of previously awarded restricted stock (not a purchase or sale). Such releases are typically the result of vesting schedules or performance/tenure conditions being met and do not by themselves indicate a change in insider market sentiment.